Literature DB >> 8553277

Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak.

M L Whiteford1, J D Wilkinson, J H McColl, F M Conlon, J R Michie, T J Evans, J Y Paton.   

Abstract

BACKGROUND: While there are reports on the outcome in adults and teenagers with cystic fibrosis of colonisation with Burkholderia (Pseudomonas) cepacia, there is little information in children.
METHODS: In December 1991 only one of 115 children with cystic fibrosis attending a paediatric centre was colonised with B cepacia. Over the next 12 months there was a rapid increase with 23 (20%) becoming colonised; eighteen (79%) of these became colonised in hospital at a time that overlapped with the admission of a B cepacia positive child. Three different bacteriocin types were isolated, with one type (S22/PO) being present in 17 (74%) patients. The outcome for children who became colonised with B cepacia was compared with that in 33 children who continued to be colonised with Pseudomonas aeruginosa alone.
RESULTS: Children colonised with B cepacia were older and more poorly nourished than those colonised with P aeruginosa, but did not have poorer pulmonary function. After colonisation, the forced expiratory volume in one second (FEV1) deteriorated between consecutive annual tests, with the average deterioration being greater in those with higher initial levels. Five children with B cepacia died from respiratory failure although none showed a fulminant deterioration. Introduction of segregation measures within hospital led to a dramatic decrease in the number of newly colonised patients.
CONCLUSIONS: This study provides further evidence for person-to-person spread of B cepacia and confirms the effectiveness of simple isolation measures in interrupting spread. Colonisation with B cepacia and P aeruginosa in children is associated with a more rapid decline in lung function and a significantly increased mortality compared with cases colonised with P aeruginosa alone.

Entities:  

Mesh:

Year:  1995        PMID: 8553277      PMCID: PMC475093          DOI: 10.1136/thx.50.11.1194

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  18 in total

1.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

2.  Pseudomonas cepacia in inpatients with cystic fibrosis.

Authors:  J W Nelson; C J Doherty; P H Brown; A P Greening; M E Kaufmann; J R Govan
Journal:  Lancet       Date:  1991-12-14       Impact factor: 79.321

3.  Pseudomonas cepacia: a new pathogen in patients with cystic fibrosis referred to a large centre in the United Kingdom.

Authors:  E J Simmonds; S P Conway; A T Ghoneim; H Ross; J M Littlewood
Journal:  Arch Dis Child       Date:  1990-08       Impact factor: 3.791

4.  Pseudomonas cepacia infection in cystic fibrosis: an emerging problem.

Authors:  A Isles; I Maclusky; M Corey; R Gold; C Prober; P Fleming; H Levison
Journal:  J Pediatr       Date:  1984-02       Impact factor: 4.406

5.  Pseudomonas cepacia: decrease in colonization in patients with cystic fibrosis.

Authors:  M J Thomassen; C A Demko; C F Doershuk; R C Stern; J D Klinger
Journal:  Am Rev Respir Dis       Date:  1986-10

6.  Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes.

Authors:  O C Tablan; W J Martone; C F Doershuk; R C Stern; M J Thomassen; J D Klinger; J W White; L A Carson; W R Jarvis
Journal:  Chest       Date:  1987-04       Impact factor: 9.410

7.  Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis.

Authors:  J J LiPuma; S E Dasen; D W Nielson; R C Stern; T L Stull
Journal:  Lancet       Date:  1990-11-03       Impact factor: 79.321

8.  Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome.

Authors:  O C Tablan; T L Chorba; D V Schidlow; J W White; K A Hardy; P H Gilligan; W M Morgan; L A Carson; W J Martone; J M Jason
Journal:  J Pediatr       Date:  1985-09       Impact factor: 4.406

9.  Pseudomonas cepacia in the hospital setting: lack of transmission between cystic fibrosis patients.

Authors:  K A Hardy; K L McGowan; M C Fisher; D V Schidlow
Journal:  J Pediatr       Date:  1986-07       Impact factor: 4.406

10.  Typing of Pseudomonas cepacia by bacteriocin susceptibility and production.

Authors:  J R Govan; G Harris
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

View more
  44 in total

1.  Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex.

Authors:  E Mahenthiralingam; T Coenye; J W Chung; D P Speert; J R Govan; P Taylor; P Vandamme
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Phenotypic methods for determining genomovar status of the Burkholderia cepacia complex.

Authors:  D A Henry; E Mahenthiralingam; P Vandamme; T Coenye; D P Speert
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

3.  Antimicrobial activity of CHIR-090, an inhibitor of lipopolysaccharide biosynthesis, against the Burkholderia cepacia complex.

Authors:  Karin Bodewits; Christian R H Raetz; John R Govan; Dominic J Campopiano
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

4.  Identification of hopanoid biosynthesis genes involved in polymyxin resistance in Burkholderia multivorans.

Authors:  Rebecca J Malott; Barbara R Steen-Kinnaird; Tracy D Lee; David P Speert
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

5.  Segregation is good for patients with cystic fibrosis.

Authors:  Steven Conway
Journal:  J R Soc Med       Date:  2008-07       Impact factor: 5.344

6.  Identification and management of unusual pathogens in cystic fibrosis.

Authors:  J Stuart Elborn
Journal:  J R Soc Med       Date:  2008-07       Impact factor: 5.344

7.  Biocide susceptibility of the Burkholderia cepacia complex.

Authors:  Helen Rose; Adam Baldwin; Christopher G Dowson; Eshwar Mahenthiralingam
Journal:  J Antimicrob Chemother       Date:  2009-01-18       Impact factor: 5.790

8.  Fosmidomycin decreases membrane hopanoids and potentiates the effects of colistin on Burkholderia multivorans clinical isolates.

Authors:  Rebecca J Malott; Chia-Hung Wu; Tracy D Lee; Trevor J Hird; Nathan F Dalleska; James E A Zlosnik; Dianne K Newman; David P Speert
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

9.  Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis.

Authors:  M R Shreve; S Butler; H J Kaplowitz; H R Rabin; D Stokes; M Light; W E Regelmann
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

10.  Molecular comparison of isolates of Burkholderia multivorans from patients with cystic fibrosis in the United Kingdom.

Authors:  Jane F Turton; Mary E Kaufmann; Nazim Mustafa; Sonia Kawa; Fiona E Clode; Tyrone L Pitt
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.